Could Cascadian Therapeutics Incorporated (NASDAQ:CASC) Go Down After Its Newest Short Interest Report?

January 14, 2018 - By Vivian Currie

 Could Cascadian Therapeutics Incorporated (NASDAQ:CASC) Go Down After Its Newest Short Interest Report?

The stock of Cascadian Therapeutics Incorporated (NASDAQ:CASC) registered a decrease of 11.95% in short interest. CASC’s total short interest was 1.65M shares in January as published by FINRA. Its down 11.95% from 1.87 million shares, reported previously. With 277,800 shares average volume, it will take short sellers 6 days to cover their CASC’s short positions. The short interest to Cascadian Therapeutics Incorporated’s float is 5.19%.

The stock increased 3.83% or $0.15 during the last trading session, reaching $4.07. About 271,162 shares traded. Cascadian Therapeutics, Inc. (NASDAQ:CASC) has declined 30.85% since January 14, 2017 and is downtrending. It has underperformed by 47.55% the S&P500.

Cascadian Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company has market cap of $205.78 million. The firm lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It currently has negative earnings. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress.

More notable recent Cascadian Therapeutics, Inc. (NASDAQ:CASC) news were published by: which released: “Cascadian Therapeutics’ (CASC) CEO Scott Myers on Q3 2017 Results – Earnings …” on November 09, 2017, also with their article: “Cascadian Therapeutics’ (CASC) CEO Scott Myers On Q2 2017 Results – Earnings …” published on August 09, 2017, published: “Cascadian Therapeutics (CASC) Announces 2018 Outlook” on January 04, 2018. More interesting news about Cascadian Therapeutics, Inc. (NASDAQ:CASC) were released by: and their article: “Cascadian Therapeutics Announces Changes to Board of Directors” published on March 13, 2017 as well as‘s news article titled: “Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in …” with publication date: July 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.